跳转至内容
Merck
CN

T9191

Anti-TRAIL antibody produced in rabbit

IgG fraction of antiserum, buffered aqueous solution

别名:

Anti-Apo-2L

登录 查看组织和合同定价。

选择尺寸


关于此项目

UNSPSC Code:
12352203
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

biological source

rabbit

conjugate

unconjugated

antibody form

IgG fraction of antiserum

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

mol wt

antigen 35 kDa

species reactivity

human

technique(s)

microarray: suitable, western blot: 1 μg/mL using human HeLa cell extract

UniProt accession no.

shipped in

wet ice

storage temp.

2-8°C

Gene Information

human ... TNFSF10(8743)

Immunogen

synthetic peptide corresponding to amino acids 261-277 of the C-terminal region of human TRAIL (TNF-Related Apoptosis-Inducing Ligand).

Physical form

Supplied as 1.0 mg/ml of IgG fraction of antiserum in phosphate buffered saline containing 0.02% sodium azide

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

未找到合适的产品?  

试试我们的产品选型工具.

存储类别

12 - Non Combustible Liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Hanjie Yi et al.
Oncology letters, 16(4), 4768-4772 (2018-09-15)
Non-small cell lung cancer (NSCLC) presents severe threats to the lives of patients. Gefitinib is one of the first-line drugs available for the treatment of NSCLC in the clinical setting. The present study investigated the effects of gefitinib on NSCLC
Ufuk Mert et al.
Cancers, 11(8) (2019-08-17)
Binding of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to the plasma membrane TRAIL-R1/-R2 selectively kills tumor cells. This discovery led to evaluation of TRAIL-R1/-R2 as targets for anti-cancer therapy, yet the corresponding clinical trials were disappointing. Meanwhile, it emerged that

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持